<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458913</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08052</org_study_id>
    <secondary_id>JJPRD-26866138CAN2012</secondary_id>
    <secondary_id>2006-000009-51</secondary_id>
    <nct_id>NCT00458913</nct_id>
  </id_info>
  <brief_title>Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma</brief_title>
  <official_title>Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as cisplatin, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving bortezomib together with&#xD;
      cisplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib&#xD;
      together with cisplatin works as first-line therapy in treating patients with malignant&#xD;
      mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity and safety of bortezomib and cisplatin as first-line treatment in&#xD;
           patients with malignant mesothelioma.&#xD;
&#xD;
        -  Validate the use of progression-free survival rate as a primary endpoint for the design&#xD;
           of phase II mesothelioma trials.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive cisplatin IV over 1 hour on day 1 and bortezomib IV over 3-5 seconds on days&#xD;
      1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate at 18 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall objective response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PFS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">82</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed pleural malignant mesothelioma, meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Recurrent disease after radical surgery&#xD;
&#xD;
               -  Disease not considered suitable for radical treatment&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No clinical evidence of brain or leptomeningeal metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min OR &gt; 50 mL/min&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times upper limit of normal (ULN) (&lt; 5 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  No concurrent secondary malignancy except carcinoma in situ of the cervix or&#xD;
             adequately treated basal cell skin cancer&#xD;
&#xD;
          -  No other malignancy treated within the past 5 years&#xD;
&#xD;
               -  Melanoma, breast cancer, or hypernephroma treated within the past 5 years and&#xD;
                  without recurrence are allowed&#xD;
&#xD;
          -  No uncontrolled or severe cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class III-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Clinically significant pericardial disease or cardiac amyloidosis&#xD;
&#xD;
          -  No infiltrative pulmonary or pericardial disease&#xD;
&#xD;
          -  No preexisting peripheral neuropathy&#xD;
&#xD;
          -  No known or suspected allergy or intolerance to boron, mannitol, or heparin, if an&#xD;
             indwelling catheter is used&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude protocol compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic chemotherapy for mesothelioma&#xD;
&#xD;
          -  No other concurrent antineoplastic agents except medications that may have&#xD;
             antineoplastic activity but are taken for other reasons (e.g., megestrol acetate,&#xD;
             cyclooxygenase-2 inhibitors, or bisphosphonates)&#xD;
&#xD;
          -  No other concurrent experimental agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary O'Brien, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 9, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

